Skip to content
Catalyst

PapersPMID:40759997

Curcumin supplementation improves the clinical outcomes of patients with diabetes and atherosclerotic cardiovascular risk.

Scientific reports2025The record ↗

findings
2
compound
1
endpoints
2
  1. Finding, moderate evidencelowersLDL cholesterol
  2. Finding, moderate evidenceraisesHDL cholesterol
Study, every finding
RCT
Dose studied, every finding
Oral Puritan's Pride Turmeric Curcumin 500 mg capsules (Curcuma longa root 450 mg plus turmeric extract 50 mg standardised to 95% curcuminoids), one capsule three times daily after meals (1500 mg/day) for 14 weeks, added to conventional therapy
Population, every finding
Adults aged 50-74 y with type 2 diabetes and a 10-year ASCVD risk score >=5%, Cairo, Egypt; 85 randomised (42 curcumin, 43 control), 72 analysed (36 per group); open-label trial in which the control arm received conventional therapy only, with no placebo; the paper declares no primary endpoint and powered its sample size on change in HDL-C; LDL-C calculated by the Friedewald equation, HDL-C by enzymatic colorimetric assay
  • “Furthermore, at the end of the study, the Curcumin group reported lower LDL levels ( P = 0.024) and higher HDL levels ( P = 0.024) versus the control group.”

Study record

Design
randomised controlled trial
Species
human
Population
Seventy-two diabetic patients (T2DM) with an ASCVD risk score of ≥ 5%; curcumin 500 mg Turmeric curcumin® thrice daily plus conventional therapy
Participants
72
Comparator
no treatment
Duration
not reported
Endpoints measured
8
Declined
another reason, stated per paper